Cantor Fitzgerald Forecasts Kura Oncology FY2026 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Kura Oncology in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek forecasts that the company will post earnings of ($2.44) per share for the year. Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The firm had revenue of $14.11 million during the quarter, compared to the consensus estimate of $39.08 million.

A number of other equities analysts have also recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Kura Oncology in a research report on Monday, April 28th. UBS Group reduced their target price on Kura Oncology from $27.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. Barclays decreased their target price on Kura Oncology from $32.00 to $11.00 and set an “overweight” rating for the company in a research note on Friday, May 2nd. Wedbush restated an “outperform” rating and issued a $36.00 price target on shares of Kura Oncology in a report on Tuesday, April 8th. Finally, Wall Street Zen lowered Kura Oncology from a “buy” rating to a “hold” rating in a research report on Friday, May 2nd. Four equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $24.50.

Kura Oncology Stock Up 1.2%

Kura Oncology stock opened at $6.81 on Tuesday. The firm has a market capitalization of $589.58 million, a price-to-earnings ratio of -2.89 and a beta of 0.40. The company’s 50 day simple moving average is $6.09 and its 200 day simple moving average is $7.58. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. Kura Oncology has a fifty-two week low of $5.41 and a fifty-two week high of $23.48.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of KURA. State of Wyoming bought a new stake in Kura Oncology in the 1st quarter valued at approximately $48,000. Virtus ETF Advisers LLC raised its holdings in shares of Kura Oncology by 71.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock valued at $64,000 after purchasing an additional 3,061 shares during the last quarter. Pallas Capital Advisors LLC bought a new stake in shares of Kura Oncology in the first quarter worth $66,000. Flower City Capital bought a new stake in shares of Kura Oncology in the first quarter worth $79,000. Finally, Magnetar Financial LLC acquired a new position in Kura Oncology during the first quarter worth $79,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.